Abstract
Patients who receive a diagnosis of metastatic castration-sensitive prostate cancer (CSPC) have different phenotypes of disease. Some of them have de novo CSPC, but others receive a late diagnosis, and still others underwent prostatectomy several years before the diagnosis of metastases. We analyze the presence of these differences in recent clinical trials in CSPC and assess the possible impact on their results.
Original language | English |
---|---|
Pages (from-to) | 482-484 |
Number of pages | 3 |
Journal | Clinical Genitourinary Cancer |
Volume | 16 |
Issue number | 6 |
DOIs |
|
Publication status | Published - Dec 1 2018 |
Keywords
- Abiraterone
- CSPC
- Docetaxel
- HSPC
- Prognosis
ASJC Scopus subject areas
- Oncology
- Urology